Abstract
Leukemia is a life threatening disease that has become increasingly common. Many categories of anti-leukemic agents have been developed by probing into the nature of leukemia. Nevertheless, the needs for potent molecules with few side effects are still not satisfied in the current anti-leukemic therapy. Targeted therapy has been developed for the advantage of relatively high efficiency and safety in the anticancer chemotherapy. Among the targeted antitumor therapies, inhibition of histone deacetylases has been intensively studied. Three histone deacetylase inhibitors (HDACIs) have been approved by US Food and Drug administration (FDA) for the treatment of cancer. Interestingly, a number of HDACIs selectively exhibited inhibitory effects on leukemic cell lines in the preclinical researches. Herein, the anti-leukemic HDACIs were reviewed to gain insight into HDACIs’ potential as anti-leukemic agents.
Keywords: Anti-leukemia, clinical trial, HDACs, inhibitor, preclinical study, selectivity.
Current Medicinal Chemistry
Title:Histone Deacetylase Inhibitors: Potent Anti-Leukemic Agents
Volume: 22 Issue: 17
Author(s): Jiang Bian, Lihui Zhang, Yantao Han, Chunbo Wang and Lei Zhang
Affiliation:
Keywords: Anti-leukemia, clinical trial, HDACs, inhibitor, preclinical study, selectivity.
Abstract: Leukemia is a life threatening disease that has become increasingly common. Many categories of anti-leukemic agents have been developed by probing into the nature of leukemia. Nevertheless, the needs for potent molecules with few side effects are still not satisfied in the current anti-leukemic therapy. Targeted therapy has been developed for the advantage of relatively high efficiency and safety in the anticancer chemotherapy. Among the targeted antitumor therapies, inhibition of histone deacetylases has been intensively studied. Three histone deacetylase inhibitors (HDACIs) have been approved by US Food and Drug administration (FDA) for the treatment of cancer. Interestingly, a number of HDACIs selectively exhibited inhibitory effects on leukemic cell lines in the preclinical researches. Herein, the anti-leukemic HDACIs were reviewed to gain insight into HDACIs’ potential as anti-leukemic agents.
Export Options
About this article
Cite this article as:
Bian Jiang, Zhang Lihui, Han Yantao, Wang Chunbo and Zhang Lei, Histone Deacetylase Inhibitors: Potent Anti-Leukemic Agents, Current Medicinal Chemistry 2015; 22 (17) . https://dx.doi.org/10.2174/0929867322666150416094720
DOI https://dx.doi.org/10.2174/0929867322666150416094720 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Influence of Lipophilicity on the Classification of Antitumor Acridinones Evaluated by Principal Component Analysis
Current Pharmaceutical Analysis Cationicity and Hydrophobicity Enhance the Cytotoxic Potency of Phoratoxin C Anticancer Peptide Analogues against Triple Negative Breast Cancer Cells
Current Bioactive Compounds The Expanding Role of Tumor Necrosis Factor-α Inhibitors in the Management of Rheumatic Diseases
Medicinal Chemistry Reviews - Online (Discontinued) Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents
Recent Patents on Regenerative Medicine Implications of Somatic Mutations in the AML1/RUNX1 Gene in Myelodysplastic Syndrome (MDS): Future Molecular Therapeutic Directions for MDS
Current Cancer Drug Targets Relaxin-Like Peptides in Neoplastic Lesions
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Recent Advances in Targeting Viral Proteases for the Discovery of Novel Antivirals
Current Topics in Medicinal Chemistry Modulation of Huntington’s Disease in Drosophila
CNS & Neurological Disorders - Drug Targets Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents
Current Pharmaceutical Design Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Thermodynamics and Electro-Biologic Prospects for Therapies to Intervene in Cancer Progression
Current Cancer Therapy Reviews Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Transition Metal Based Anticancer Drugs
Current Topics in Medicinal Chemistry Understanding XPO1 Target Networks Using Systems Biology and Mathematical Modeling
Current Pharmaceutical Design The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Genes Associated with Epithelial-Mesenchymal Transition: Possible Therapeutic Targets in Ductal Pancreatic Adenocarcinoma?
Anti-Cancer Agents in Medicinal Chemistry